The Daily Dish (08/09/21)

DraftKings Announces Deal to Buy Golden Nugget for $1.56 Billion  

DraftKings has agreed to buy Golden Nugget Online Gaming Inc for $1.56 Billion, in a deal that sees the Houston Rockets owner join the fantasy sports betting firm with over 5 million customers.

Fertitta, which owns a 46% stake in Golden Nugget, has agreed to continue holding shares for a minimum of one year after the SPAC transaction closes. 

As part of the new deal, DraftKings said that it would form a new holding company called New DraftKings, which would contain both DraftKings and Golden Nugget, which owns Landry’s portfolio of restaurants.

In a deal that is all stock, shareholders of Golden Nugget will receive 0.365 shares of New DraftKings stock for each share held.  

Th transaction is expected to close in the first quarter of 2022. Golden Nugget’s parent company Fertitta Entertainment, agreed to go public through a SPAC merger. DraftKings used a similar route to go public in April last year. 

Qualcomm Looking to Buy Auto Parts Maker Veoneer 

Qualcomm is planning to hold talks with Swedish automotive technology company Veoneer in a bid to acquire the company. A recent offer from Qualcomm is likely to constitute a ‘superior bid’ under the terms of a previous acquisition bid Veoneer’s board had approved with Magna International.

Despite the discussions with Qualcomm, Veoneer has not withdrawn from its agreement with Magna. 

Veoneer stated in its announcement that terminating the deal with Magna would require payment of a $110 million termination fee. Reports suggest that Qualcomm has made a $4.6 billion bid for Veoneer, which would represent an 18.4% premium over Magna’s.

The Qualcomm bid comes after two major recent announcements in the automotive technology sector. This includes Toyota adding mobility services to its fleet of self driving cars and driverless car startup Aurora announcing that it would go public through a SPAC merger. 

EQRx Signs $2 Billion SPAC Merger with CM Life Sciences 

EQRx, a pharmaceutical company which specializes in developing drug candidates for cancer and inflammatory conditions announced that it had entered a definitive SPAC merger agreement with CM Life Sciences, with the combined company valued at $2 Billion.

Using established drug targets, the company expects its candidates to have an increased probability of regulatory success, reduced risk adjusted cost of drug development and a more efficient access model. 

The company’s pipeline has more than 10 programs, including two pre-registration oncology assets, aumolertinib and sugemalimab, which provided favourable Phase III data.

Furthermore, the company is bolstering its portfolio through engineering partnerships with major drug discovery such as Exscientia and AbCellera Biologics. The funding comprises $552 million in cash held in CM Life Sciences’ trust account as well as $1.2 billion from a committed PIPE placement. 

The Headlines


Share on twitter
Share on reddit
Share on facebook
Share on linkedin

Leave a Reply

Your email address will not be published. Required fields are marked *

Social Media

Most Popular

Get The Latest Updates

Subscribe To Our Weekly Newsletter

No spam, notifications only about new products, updates.


On Key

Related Posts

Short Sellers Give Up

Today we Cover $WALD, $HYZN, $DNA, and more… While De-SPACs may have seemed like easy targets for short-sellers a few months ago, the combination of

Crash and Burn

Today we cover $PSFE, $RIDE, $BKSY and more… As more De-SPACs report Q3, premium valuations and lofty projections catch up to some companies. In today’s

SPACs Outperform in Q3

Today we cover $SOFI, $PAYO, $UTAA, and more… As the earnings season kicks into full gear, SPACs are delivering better than expected earnings and continue

Will Circle change the banking world?

The Rundown – Your weekly SPAC Deep Dive (11/10/21) What’s up everyone, Despite several attempts at banning or severely restricting a decentralized economy, cryptocurrencies have